Corporate Division Head Medical Oncology/Hematology, William Osler Health System
BIOGRAPHY
Abstract
Turnaround time impacts on care, IHC and NGS result partnership, in-house testing lab relationships, and motivations for internal/external send-out.
You May Also Like
MAR 26, 2024 | 7:00 PM
C.E. CREDITS
The implementation of a preemptive pharmacogenomics (PGx) program in a hospital setting requires a multidisciplinary approach to ensure seamless integration of each stage of the process for...
MAR 26, 2024 | 8:00 AM
C.E. CREDITS
The implementation of a preemptive pharmacogenomics (PGx) program in a hospital setting requires a multidisciplinary approach to ensure seamless integration of each stage of the process for...
DEC 12, 2023 15:00 CET
C.E. CREDITS
The implementation of the new CE-In Vitro Diagnostics Regulation (IVDR) involves challenges faced by labs that are working within the diagnostic environment. The aim of this event is to get...
OCT 24, 2023 | 8:00 AM
To bring your cutting-edge cell and gene therapies to the patients that need them as quickly as possible, you need access to the most knowledgeable scientists, innovative technologies, metho...
MAR 26, 2024 | 11:00 AM
Ever wonder what you’re missing in your data? The sheer complexity of today’s flow and mass cytometry datasets demands automated solutions. Machine learning plugins only provide...
OCT 24, 2023 | 10:00 AM
Dynamic changes in chromatin drive gene expression programs during cellular development and contribute to pathological changes underlying disease. To date, efforts to characterize chromatin...
Loading Comments...
Finish Registering
-
APR 30, 2024Immuno-Oncology Virtual Event Series 2024 -
MAY 07, 20243rd International Biosecurity Virtual Symposium
-
JUN 06, 2024The Future of Scientific Conferencing
- See More
-
APR 23, 2024
- See More
